A detailed history of Credit Suisse Ag transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 123,970 shares of PCVX stock, worth $10.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
123,970
Previous 97,803 26.75%
Holding current value
$10.7 Million
Previous $6.14 Million 37.87%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$59.79 - $81.05 $1.56 Million - $2.12 Million
26,167 Added 26.75%
123,970 $8.47 Million
Q4 2023

Feb 08, 2024

BUY
$45.35 - $63.41 $525,651 - $734,985
11,591 Added 13.44%
97,803 $6.14 Million
Q3 2023

Nov 13, 2023

SELL
$46.0 - $53.1 $342,378 - $395,223
-7,443 Reduced 7.95%
86,212 $4.4 Million
Q2 2023

Aug 11, 2023

BUY
$34.66 - $54.07 $1.56 Million - $2.43 Million
44,984 Added 92.42%
93,655 $4.68 Million
Q1 2023

May 10, 2023

BUY
$36.27 - $47.2 $205,505 - $267,435
5,666 Added 13.18%
48,671 $1.82 Million
Q4 2022

Feb 13, 2023

BUY
$20.58 - $47.95 $279,167 - $650,441
13,565 Added 46.08%
43,005 $2.06 Million
Q3 2022

Nov 10, 2022

BUY
$21.69 - $28.53 $120,227 - $158,141
5,543 Added 23.2%
29,440 $706,000
Q2 2022

Aug 12, 2022

BUY
$17.68 - $26.58 $126,694 - $190,472
7,166 Added 42.83%
23,897 $520,000
Q1 2022

May 16, 2022

SELL
$17.46 - $26.36 $6,268 - $9,463
-359 Reduced 2.1%
16,731 $405,000
Q4 2021

Feb 14, 2022

BUY
$19.32 - $26.45 $74,652 - $102,202
3,864 Added 29.22%
17,090 $406,000
Q3 2021

Nov 12, 2021

BUY
$20.26 - $26.97 $38,818 - $51,674
1,916 Added 16.94%
13,226 $337,000
Q2 2021

Aug 16, 2021

SELL
$16.45 - $24.06 $28,491 - $41,671
-1,732 Reduced 13.28%
11,310 $254,000
Q1 2021

May 14, 2021

SELL
$18.66 - $29.16 $386,150 - $603,437
-20,694 Reduced 61.34%
13,042 $257,000
Q4 2020

Feb 12, 2021

BUY
$26.57 - $51.74 $896,365 - $1.75 Million
33,736 New
33,736 $895,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.1B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.